AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26496327 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided therapy (GGT) with peginterferon-alpha/ribavirin (HCV genotype 1: 48 weeks; HCV genotype 2/3: 24 weeks)
Number of subjects: 203
Study 26496327 — intervention group
Group type: COMPARATOR
Intervention: Response-guided therapy (RGT) with peginterferon-alpha/ribavirin (HCV genotype 1: 48 or 24 weeks if baseline VL <400,000 IU/mL and RVR; HCV genotype 2/3: 24 or 16 weeks if RVR)
Number of subjects: 203
Study 26496327 — intervention group
Group type: COMPARATOR
Intervention: RGT in HCV-1/HBV dually infected patients
Number of subjects: 203
Study 24397355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hand performance task with affected hand
Number of subjects: 15
Study 24397355 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 24397355 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hand capacity task
Number of subjects: 15
Study 22928275 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based educational program
Number of subjects: 40
Study 22928275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 19131153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ormocer-based composite (AD, Admira/Admira Bond, VOCO)
Number of subjects: 32
Study 19131153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ormocer-based composite (DE, Definite/Etch & Prime 3.0, Dentsply)
Number of subjects: 32
Study 19131153 — intervention group
Group type: EXPERIMENTAL
Intervention: Bis-GMA-based composite (TC, Tetric-Ceram/Syntac, Ivoclar-Vivadent)
Number of subjects: 32
Study 19131153 — intervention group
Group type: EXPERIMENTAL
Intervention: All restorations
Number of subjects: 32
Study 19131153 — intervention group
Group type: EXPERIMENTAL
Intervention: DE (Definite/Etch & Prime 3.0, Dentsply)
Number of subjects: 32
Study 17472615 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutrimazole shampoo 1%
Number of subjects: 60
Study 17472615 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole shampoo 2%
Number of subjects: 60
Study 15690558 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led asthma education program in intervention schools
Number of subjects: 4475
Study 15690558 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 4475
Study 11559721 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptides/IFA with IL-12 30 ng/kg
Number of subjects: 48
Study 11559721 — intervention group
Group type: COMPARATOR
Intervention: Peptides/IFA without IL-12
Number of subjects: 48
Study 9834891 — intervention group
Group type: EXPERIMENTAL
Intervention: All-minutes measurement strategy
Number of subjects: 0
Study 9834891 — intervention group
Group type: COMPARATOR
Intervention: Odd-minutes measurement strategy
Number of subjects: 0
Study 7856296 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titre Edmonston-Zagreb (EZ-H), potency 5.7 log10/dose
Number of subjects: 1023
Study 7856296 — intervention group
Group type: COMPARATOR
Intervention: Medium-titre Edmonston-Zagreb (EZ-M), potency 4.7 log10/dose
Number of subjects: 1023
Study 7856296 — intervention group
Group type: EXPERIMENTAL
Intervention: AIK-C, potency 5.5 log10/dose
Number of subjects: 1023
Study 7856296 — intervention group
Group type: COMPARATOR
Intervention: Edmonston-Zagreb (EZ-H)
Number of subjects: 1023
Study 7856296 — intervention group
Group type: EXPERIMENTAL
Intervention: AIK-C (after revaccination at age 9.5 months)
Number of subjects: 1023
Study 7856296 — intervention group
Group type: COMPARATOR
Intervention: Edmonston-Zagreb (EZ-H) (after revaccination at age 9.5 months)
Number of subjects: 1023
Study 2543223 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogens for 21 days plus placebo during the last 10 days of each cycle
Number of subjects: 22
Study 2543223 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg medrogestone per day for 10 days in conjunction with conjugated equine estrogens
Number of subjects: 22
Study 2543223 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 22
Study 1228536 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy followed by chemotherapy
Number of subjects: 0
Study 1228536 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 0
Study 31703586 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic observation process for population randomization
Number of subjects: 400
Study 31703586 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of secondary segments due to high vacancy
Number of subjects: 400
Study 31703586 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of tertiary segments
Number of subjects: 400
Study 29255347 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg) administered once daily for 7 days as monotherapy
Number of subjects: 25
Study 29255347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) administered once daily for 7 days as monotherapy
Number of subjects: 25
Study 29255347 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of rosuvastatin and ezetimibe
Number of subjects: 25
Study 25680984 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of oligoclonal bands (OCB)
Number of subjects: 1047
Study 25680984 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of T2 lesions (2 to 9 lesions vs 0/1 lesions)
Number of subjects: 1047
Study 25680984 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of T2 lesions (>9 lesions vs 0/1 lesions)
Number of subjects: 1047
Study 25680984 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at CIS
Number of subjects: 1047
Study 25680984 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D3 (25-OH-D) levels
Number of subjects: 1047
Study 23525316 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of oral 25% glucose solution
Number of subjects: 124
Study 23525316 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral glucose solution)
Number of subjects: 124
Study 20386134 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 9
Study 20386134 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO supplementation
Number of subjects: 9
Study 20386134 — intervention group
Group type: COMPARATOR
Intervention: PLAC beverage
Number of subjects: 9
Study 19720913 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus bevacizumab
Number of subjects: 0
Study 19720913 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 0
Study 15809781 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted adrenalectomy (ROBOT) using the da Vinci robotic system
Number of subjects: 20
Study 15809781 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic adrenalectomy (LAP)
Number of subjects: 20
Study 11719734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet with rofecoxib (25 mg twice daily)
Number of subjects: 6
Study 11719734 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet without rofecoxib
Number of subjects: 6
Study 11719734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous furosemide (20 mg)
Number of subjects: 6
Study 11719734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet with furosemide and rofecoxib
Number of subjects: 6
Study 11719734 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet
Number of subjects: 6
Study 11719734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous furosemide
Number of subjects: 6
Study 8986145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose methotrexate (IDM) plus intrathecal methotrexate (IT MTX)
Number of subjects: 596
Study 8986145 — intervention group
Group type: COMPARATOR
Intervention: Cranial radiation (CRT) plus IT MTX
Number of subjects: 596
Study 8986145 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 596
Study 8318400 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone administration added to the antiemetic effect of ondansetron
Number of subjects: 42
Study 8318400 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron as a single antiemetic agent
Number of subjects: 42
Study 3539349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 0
Study 3539349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3539349 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg
Number of subjects: 0
Study 3539349 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1,600 mg
Number of subjects: 0
Study 30883486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic IVA training
Number of subjects: 8
Study 30883486 — intervention group
Group type: COMPARATOR
Intervention: Static IVA training
Number of subjects: 8
Study 29114847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal anti-tissue transglutaminase 2 immunoglobulin A (anti-TG2) deposits
Number of subjects: 62
Study 29114847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal deposits in potential CD patients
Number of subjects: 62
Study 29114847 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive diagnosis of CD after biopsy
Number of subjects: 62
Study 29114847 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TG2 deposits in normal mucosal architecture
Number of subjects: 62
Study 27418208 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT + HT
Number of subjects: 101
Study 27418208 — intervention group
Group type: COMPARATOR
Intervention: CRT
Number of subjects: 101
Study 25032115 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal resection (SMR)
Number of subjects: 60
Study 25032115 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency turbinate volume reduction (RFTVR)
Number of subjects: 60
Study 22619887 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 26
Study 22619887 — intervention group
Group type: COMPARATOR
Intervention: Neuronox
Number of subjects: 26
Study 19804542 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 65
Study 19804542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 17852146 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Number of subjects: 1020
Study 17852146 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone (FSH)
Number of subjects: 1020
Study 17852146 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone (LH)
Number of subjects: 1020
Study 17852146 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between E2 and FSH
Number of subjects: 1020
Study 17852146 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between FSH and LH
Number of subjects: 1020
Study 17852146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity effect on hormone levels
Number of subjects: 1020
Study 17852146 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) effect on hormone levels
Number of subjects: 1020
Study 17852146 — intervention group
Group type: EXPERIMENTAL
Intervention: Age effect on hormone levels
Number of subjects: 1020
Study 16110136 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF 4 microg/kg/d subcutaneous
Number of subjects: 92
Study 16110136 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 92
Study 11875141 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding advancement
Number of subjects: 99
Study 11875141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean gastric residual volume (GRV)
Number of subjects: 99
Study 11875141 — intervention group
Group type: EXPERIMENTAL
Intervention: Green gastric residuals (GR)
Number of subjects: 99
Study 9952063 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine alone (2 mg)
Number of subjects: 12
Study 9952063 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine with naloxone (2:1 ratio)
Number of subjects: 12
Study 9952063 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine with naloxone (4:1 ratio)
Number of subjects: 12
Study 9952063 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine with naloxone (8:1 ratio)
Number of subjects: 12
Study 9952063 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone (15 mg)
Number of subjects: 12
Study 9952063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7780091 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate (CHO) diet
Number of subjects: 27
Study 7780091 — intervention group
Group type: EXPERIMENTAL
Intervention: High lipid (LIPID) diet
Number of subjects: 27
Study 7780091 — intervention group
Group type: COMPARATOR
Intervention: No food (control)
Number of subjects: 27
Study 1965290 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.30% soluble pyrophosphate and 1.50% copolymer
Number of subjects: 0
Study 1965290 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.30% soluble pyrophosphate without copolymer
Number of subjects: 0
Study 1965290 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (no anticalculus ingredients)
Number of subjects: 0
Study 87408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 11
Study 87408 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study 31621838 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg
Number of subjects: 63
Study 31621838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 31320281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0
Study 31320281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27230561 — intervention group
Group type: EXPERIMENTAL
Intervention: AdaptivCRT™ (aCRT)
Number of subjects: 60
Study 27230561 — intervention group
Group type: COMPARATOR
Intervention: echo-optimized
Number of subjects: 60
Study 26234838 — intervention group
Group type: EXPERIMENTAL
Intervention: EMBOL-X device (group-1)
Number of subjects: 30
Study 26234838 — intervention group
Group type: COMPARATOR
Intervention: No EMBOL-X device (group-2)
Number of subjects: 30
Study 26234838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 23706949 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 759
Study 23706949 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 759
Study 23706949 — intervention group
Group type: COMPARATOR
Intervention: sham injection
Number of subjects: 759
Study 23706949 — intervention group
Group type: EXPERIMENTAL
Intervention: sham/0.5 mg ranibizumab after crossover
Number of subjects: 759
Study 21631446 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 21631446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21631446 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene treatment
Number of subjects: 0
Study 21631446 — intervention group
Group type: COMPARATOR
Intervention: Combination metformin/clomiphene treatment
Number of subjects: 0
Study 19306304 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 2875
Study 16648502 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional failure (IBTR and oLRR)
Number of subjects: 2669
Study 16648502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of IBTR
Number of subjects: 2669
Study 16648502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of oLRR
Number of subjects: 2669
Study 16648502 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year DDFS after IBTR
Number of subjects: 2669
Study 16648502 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year DDFS after oLRR
Number of subjects: 2669
Study 16648502 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year OS after IBTR
Number of subjects: 2669
Study 16648502 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year OS after oLRR
Number of subjects: 2669
Study 16648502 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard ratio for mortality associated with IBTR
Number of subjects: 2669
Study 16648502 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard ratio for mortality associated with oLRR
Number of subjects: 2669
Study 14697110 — intervention group
Group type: EXPERIMENTAL
Intervention: Penn State Children's Hospital Sedation Algorithm (PSCHSA)
Number of subjects: 0
Study 14697110 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (before PSCHSA implementation)
Number of subjects: 0
Study 11370756 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based preventive program with salivary lactobacillus counts as a sugar-motivating tool
Number of subjects: 936
Study 11370756 — intervention group
Group type: COMPARATOR
Intervention: Reference group (students from a neighboring district with no dental health-promoting activities)
Number of subjects: 936
Study 9146515 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation with PLLA screws (group II)
Number of subjects: 20
Study 9146515 — intervention group
Group type: COMPARATOR
Intervention: Fixation with titanium screws (group I)
Number of subjects: 20
Study 8174881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 10
Study 8174881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3230278 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone at a dosage of 0.25 mg/kg daily for 6 months
Number of subjects: 18
Study 3230278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29729347 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐COCC
Number of subjects: 151
Study 29729347 — intervention group
Group type: COMPARATOR
Intervention: Video alone
Number of subjects: 151
Study 29729347 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study 27312076 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus ivabradine (I + SDT)
Number of subjects: 58
Study 27312076 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SDT)
Number of subjects: 58
Study 24716466 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive tobacco treatment intervention (proactive outreach with mailed invitations and telephone calls, access to free NRT and intensive telephone-based behavioral counseling)
Number of subjects: 2500
Study 24716466 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2500
Study 22034522 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body-based preventive intervention program (yoga postures, visualization, social exercises, breathing techniques); Duration: 5 weekly sessions.
Number of subjects: 54
Study 22034522 — intervention group
Group type: COMPARATOR
Intervention: Control condition; No specific intervention details provided.
Number of subjects: 54
Study 20536952 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg once weekly for 4 weeks, followed by maintenance at 20 mg or titration to 30 mg or 40 mg for an additional 4 weeks.
Number of subjects: 129
Study 20536952 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 30 mg once weekly for 4 weeks (after initial 20 mg).
Number of subjects: 129
Study 20536952 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 40 mg once weekly for 4 weeks (after initial 20 mg).
Number of subjects: 129
Study 20536952 — intervention group
Group type: COMPARATOR
Intervention: Placebo.
Number of subjects: 129
Study 18419347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 0
Study 18419347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14715833 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TSH (rTSH) stimulation
Number of subjects: 7
Study 14715833 — intervention group
Group type: COMPARATOR
Intervention: TSH suppression
Number of subjects: 7
Study 11331495 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous double loop closure technique
Number of subjects: 100
Study 11331495 — intervention group
Group type: COMPARATOR
Intervention: Continuous mass closure technique
Number of subjects: 100
Study 9302491 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill running
Number of subjects: 8
Study 9302491 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-level running
Number of subjects: 8
Study 9302491 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill running
Number of subjects: 8
Study 7930251 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate infusion
Number of subjects: 19
Study 7930251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitrate infusion)
Number of subjects: 19
Study 7930251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate administration
Number of subjects: 19
Study 2896508 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 275
Study 2896508 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg twice daily
Number of subjects: 275
Study 2896508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 28929362 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise condition (30-min moderate-intensity exercise at 67% HR maximum)
Number of subjects: 26
Study 28929362 — intervention group
Group type: COMPARATOR
Intervention: Sedentary condition (30-min sitting)
Number of subjects: 26
Study 26780184 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure-lowering treatment
Number of subjects: 35
Study 26780184 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure-lowering treatment excluding baseline heart failure
Number of subjects: 35
Study 26780184 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 35
Study 26780184 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists with concomitant use of diuretics, beta-blockers or renin-angiotensin system blockers
Number of subjects: 35
Study 25172198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment of glycemia (hemoglobin A1c target <6.0%)
Number of subjects: 2856
Study 25172198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate plus simvastatin
Number of subjects: 2856